

Article 34
 1. Use of a LHRH analog or a combination of LHRH analogs and an antiestrogen with tissue-selective estrogenic effect which is selected from the group of compounds Raloxifen, Droloxifen, Centchroman, or their derivatives, for treatment of gynecological conditions, especially for treatment of endometrioses and myomas.

2. Use as claimed in claim 1, wherein the LHRH analog is a LHRH agonist or LHRH antagonist.

3. Use as claimed in claim 1 or 2, wherein the LHRH analog is selected from the group of compounds Leuprorelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂, Ramorelix, Zoladex or their derivatives,

4. Use as claimed in ^{claim 1} ~~one of claims 1 to 3~~, wherein the LHRH analog or combination of LHRH analogs is orally bioavailable.

5. Use as claimed in ^{claim 1} ~~one of claims 1 to 4~~, wherein the LHRH analog is a (non-peptidergic) LHRH agonist or antagonist.

6. Use as claimed in ^{claim 1} ~~one of claims 1 to 5~~, wherein the antiestrogen is of the Raloxifen type.

7. Use as claimed in ^{claim 1} ~~one of claims 1 to 6~~, wherein the two active ingredients are present in separate forms of administration.

8. Use as claimed in ^{claim 1} ~~one of claims 1 to 6~~, wherein the two active ingredients are present in ^{common} ~~separate~~ forms of administration.

9. Use as claimed in claim 7 or 8, wherein the LHRH analog and antiestrogen are used at the same time and/or sequentially in time.

add B2

add C1

add E2

add G1

add H3
 add H4

09117357.0922098